ITB-MED AB
Developing novel antibody therapy to eliminate post-transplant immunosuppression needs.
Oversigt
- 10–19
- Medarbejdere
- 50–100mio SEK
- Omsætning
- 2015
- Grundlagt
Beskrivelse
ITB-MED is a specialized biotechnology company focused on transforming organ transplantation outcomes. The organization is developing TCD601 (siplizumab), a proprietary antagonistic CD2-directed monoclonal antibody. This novel therapy aims to achieve transplantation tolerance, potentially freeing pa...